P.C. Huijgens

746 total citations
32 papers, 535 citations indexed

About

P.C. Huijgens is a scholar working on Hematology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P.C. Huijgens has authored 32 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P.C. Huijgens's work include Multiple Myeloma Research and Treatments (6 papers), Acute Myeloid Leukemia Research (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). P.C. Huijgens is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Acute Myeloid Leukemia Research (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). P.C. Huijgens collaborates with scholars based in Netherlands, United States and France. P.C. Huijgens's co-authors include G.J. Ossenkoppele, Sonja Zweegman, G.J. Timmers, A. M. Simoons‐Smit, Andries R. Jonkhoff, Bob Löwenberg, LF Verdonck, G. J. Ossenkoppele, A. C. Van Loenen and Daan J. Touw and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

P.C. Huijgens

31 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P.C. Huijgens Netherlands 15 198 162 145 140 97 32 535
Morel Rubinger Canada 15 307 1.6× 306 1.9× 73 0.5× 120 0.9× 96 1.0× 38 723
TR Spitzer United States 7 328 1.7× 174 1.1× 52 0.4× 126 0.9× 74 0.8× 11 555
Hyun-Sook Chi South Korea 13 225 1.1× 101 0.6× 80 0.6× 79 0.6× 58 0.6× 33 503
Anthony J. Perissinotti United States 14 166 0.8× 175 1.1× 113 0.8× 97 0.7× 173 1.8× 67 606
Tzeon Jye Chiou Taiwan 14 109 0.6× 257 1.6× 54 0.4× 309 2.2× 89 0.9× 35 638
Alex Ganetsky United States 13 154 0.8× 177 1.1× 114 0.8× 109 0.8× 52 0.5× 35 504
Moussab Damlaj Saudi Arabia 13 193 1.0× 136 0.8× 190 1.3× 76 0.5× 67 0.7× 65 625
José Luis Pico France 7 87 0.4× 117 0.7× 111 0.8× 72 0.5× 41 0.4× 7 388
Stuart Seropian United States 13 342 1.7× 297 1.8× 255 1.8× 107 0.8× 44 0.5× 26 761
C. H. Tzeng Taiwan 13 180 0.9× 133 0.8× 41 0.3× 157 1.1× 55 0.6× 34 491

Countries citing papers authored by P.C. Huijgens

Since Specialization
Citations

This map shows the geographic impact of P.C. Huijgens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.C. Huijgens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.C. Huijgens more than expected).

Fields of papers citing papers by P.C. Huijgens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.C. Huijgens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.C. Huijgens. The network helps show where P.C. Huijgens may publish in the future.

Co-authorship network of co-authors of P.C. Huijgens

This figure shows the co-authorship network connecting the top 25 collaborators of P.C. Huijgens. A scholar is included among the top collaborators of P.C. Huijgens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.C. Huijgens. P.C. Huijgens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Allard, R.H.B., et al.. (2004). [Antithrombotic therapy and dental surgery with bleeding].. PubMed. 111(12). 482–5. 7 indexed citations
2.
Berends, Frits J., N.W.L. Schep, Miguel A. Cuesta, et al.. (2004). Hematological long-term results of laparoscopic splenectomy for patients with idiopathic thrombocytopenic purpura: a case control study. Surgical Endoscopy. 18(5). 766–770. 21 indexed citations
3.
Ossenkoppele, GJ, et al.. (2003). PCHI4: MEDICAL TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML):AVERAGE COST EFFECTIVENESS RATIOS OF FIRST AND SECOND LINE TREATMENT. Value in Health. 6(3). 233–233. 1 indexed citations
4.
Agthoven, Michel van, Carin A. Uyl‐de Groot, Pieter Sonneveld, et al.. (2002). Cost analysis of CHOP (‐like) chemotherapy regimens for patients with newly diagnosed aggressive non‐Hodgkin's lymphoma. European Journal Of Haematology. 69(4). 213–220. 9 indexed citations
5.
Zweegman, Sonja & P.C. Huijgens. (2002). Treatment of myeloma: recent developments. Anti-Cancer Drugs. 13(4). 339–351. 9 indexed citations
6.
Groot, Carin A. Uyl‐de, et al.. (2001). Costs of Diagnosis, Treatment, and Follow Up of Patients with Acute Myeloid Leukemia in the Netherlands. Journal of Hematotherapy & Stem Cell Research. 10(1). 187–192. 22 indexed citations
7.
8.
9.
Timmers, G.J., et al.. (1999). DEEP VEIN THROMBOSIS AS A PRESENTING SYMPTOM OF CONGENITAL INTERRUPTION OF THE INFERIOR VENA CAVA. International Journal of Clinical Practice. 53(1). 75–76. 49 indexed citations
10.
Zevenbergen, Adri, et al.. (1999). Role of TNFα in bryostatin-induced inhibition of human hematopoiesis. Leukemia. 13(1). 62–69. 5 indexed citations
11.
Huijgens, P.C., A. M. Simoons‐Smit, A. C. Van Loenen, et al.. (1999). Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.. Journal of Clinical Pathology. 52(5). 376–380. 57 indexed citations
12.
Leijdekkers, V.J., et al.. (1999). Risk Factors for Premature Atherosclerosis. European Journal of Vascular and Endovascular Surgery. 17(5). 394–397. 5 indexed citations
13.
Zweegman, Sonja, et al.. (1999). Megakaryocytic differentiation of human progenitor cells is negatively influenced by direct contact with stroma. Leukemia. 13(6). 935–943. 17 indexed citations
14.
Dekker, A. W., Mars B. vanʼt Veer, W Sizoo, et al.. (1997). Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.. Journal of Clinical Oncology. 15(2). 476–482. 49 indexed citations
15.
Ossenkoppele, G.J., G.J. Schuurhuis, Andries R. Jonkhoff, et al.. (1996). High-dose melphalan with re-infusion of unprocessed, G-CFS-primed whole blood is effective and non-toxic therapy in multiple myeloma. European Journal of Cancer. 32(12). 2058–2063. 10 indexed citations
16.
Janssen, Jeroen J. W. M., et al.. (1996). Outcome of ICU treatment in invasive aspergillosis. Intensive Care Medicine. 22(12). 1315–1322. 45 indexed citations
17.
Ossenkoppele, G. J., et al.. (1996). Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation.. PubMed. 17(6). 963–71. 14 indexed citations
18.
Raemaekers, John, et al.. (1995). Two hours iv infusion of 2-chlorodeoxyadenosine (2-CDA) in hairy cell leukemia (HCL) is effective and may produce less CD34/CD8 ratio impairment. Results from the HOVON-23 study. Blood. 86. 2 indexed citations
19.
Daenen, Simon, Bob Löwenberg, Pieter Sonneveld, et al.. (1994). Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).. PubMed. 8(1). 6–10. 26 indexed citations
20.
Huijgens, P.C., G.J. Ossenkoppele, A. C. Van Loenen, et al.. (1991). Imipenem‐cilastatin for empirical therapy in neutropenic patients with fever: An open study in patients with hematologic malignancies. European Journal Of Haematology. 46(1). 42–46. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Morel Rubinger Breakdown of academic impact, for papers by TR Spitzer Breakdown of academic impact, for papers by Hyun-Sook Chi Breakdown of academic impact, for papers by Anthony J. Perissinotti Breakdown of academic impact, for papers by Tzeon Jye Chiou Breakdown of academic impact, for papers by Alex Ganetsky Breakdown of academic impact, for papers by Moussab Damlaj Breakdown of academic impact, for papers by José Luis Pico Breakdown of academic impact, for papers by Stuart Seropian Breakdown of academic impact, for papers by C. H. Tzeng
Rankless by CCL
2026